NCT06057233Not yet recruiting
Innovative MRI to Localize the Epileptic Zone
Quantitative MRI and GABA Spectroscopy to Localize the Epileptic Zone
Source: ClinicalTrials.gov · Last updated 23 Aug 2024 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
The goal of EPI-CATCHER is to outline the clinical potential of multiparametric quantitative MRI (mqMRI) and of GABA-edited magnetic resonance spectroscopy (GABA-MRS), combined with machine learning tools, as imaging biomarkers to localize and delineate the EZ.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 40 (estimated)
- First submitted
- 19 Sept 2023
- Start date
- Oct 2024
- Primary completion date
- Nov 2028
- Lead sponsor
- University Hospital, Grenoble
- Diseases
- Epilepsy
- NCT number
- NCT06057233
What you commit to
- Study type: Observational
- Planned participants: 40
- From Oct 2024 to the primary completion date, Nov 2028
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Patient group
- Patient without social security system
- Inability or unwillingness of the individual to provide written informed consent, according to national regulations.
- Impossibility of collecting information on exposure (subjects recently arrived in France, foreign language, etc.),
- Contraindication for MRI,
- Contraindication for injection of MRI contrast agent (Gd-Chelate),
- Evidence on neuroimaging (CT or MRI) of a brain lesion in the same hemisphere as the EZ (tumor, stroke, cerebral edema with midline shift and a clinically significant compression of ventricles, or subarachnoid hemorrhage, or intracerebral parenchymal hematoma (petechial small hemorrhages are NOT a non-inclusion criteria),
- Severe leucoariosis
- Pre-existing dementia
- Pregnant, breastfeeding women
- Reference group
- Person who is participating in another therapeutic trial
- Person with a psychiatric disorder, an epilepsy, or a brain lesion susceptible to impact the MRI readouts
- Person without social security system,
- Inability or unwillingness of the individual to provide written informed consent, according to national regulations,
- Impossibility of collecting information on exposure (subjects recently arrived in France, foreign language, etc.),
- Contraindication for MRI
- Contraindication for injection of MRI contrast agent (Gd-Chelate)
- Pregnant, breastfeeding woman.
Who the study is looking for
- Patient group
- Patients aged 18-65 years,
- Patients with drug-resistant focal epilepsy,
- Patients with MTLE suspicion, with normal MRI or hippocampal sclerosis, and candidate for surgery,
- Negative pregnancy test for child-bearing aged woman,
- Obtained signed informed consent from patient
- Reference group
- Male or female, 18-65 years,
- Obtained signed informed consent from participants,
- Negative pregnancy test for child-bearing aged woman
Age in the registry: 18 years to 65 years · Sex: All · Accepts healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.